Eos Biosciences announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,757,386, which covers composition of matter and method of use for Eos Biosciences’ theranostic product Eos-002, a HER3-targeted Eosome with manganese corrole payload. HER3 is over-expressed on many types of metastatic and drug-resistant solid tumors.
April 21, 2016 – Eos Biosciences, Inc. recruited Thomas Plotts to join the company as its Chief Financial Officer. Plotts previously served as Chief Financial Officer and Vice President, Finance at Los Angeles Biomedical Research Institute, a world-class independent biomedical research institute focused on the discover, causes and genetic underpinnings of rare, chronic and infectious diseases. [...]
Eos Biosciences, Inc. completed its seed financing round in January, 2015 and is now in the process of rounding out its Series A financing, already having secured follow-on participation from all of the investors in the company’s seed round.
Eos Biosciences, Inc. adds Peter Linsley, Ph.D. and Michael Kahn, Ph.D. to the company’s Science Advisory Board. Dr. Linsley an expert in RNAi therapeutics, Oncology and Immunology is currently a Research Associate Member at the Benaroya Research Institute. Dr. Kahn has expertise in Oncology, Peptidomimetics and Molecular & Cell Biology and is currently Provost Professor [...]
Eos Biosciences, Inc. and Cedars-Sinai Medical Center sign a license agreement, providing Eos Biosciences with an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed by Dr. Lali Medina-Kauwe at Cedars-Sinai Medical Center. The agreement covers nanopartical technology patent rights for use in the prevention, treatment or diagnosis of diseases.